<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528267</url>
  </required_header>
  <id_info>
    <org_study_id>08/H0708/100</org_study_id>
    <nct_id>NCT01528267</nct_id>
  </id_info>
  <brief_title>Bronchoscopic Lung Volume Reduction Using Blood</brief_title>
  <official_title>A Randomised, Double Blind, Sham Controlled Trial of Autologous Blood Lung Volume Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chelsea and Westminster NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chelsea and Westminster NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prupose of this study is to determine the feasibility, effectiveness, and safety of&#xD;
      injecting blood into the airways to cause lung volume reduction in people with severe&#xD;
      emphysema.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomised, double blind, placebo controlled trial where the response in&#xD;
      patients treated with blood LVR will be compared to patients treated with placebo (control&#xD;
      group). Analysis will evaluate the mean change in lobar lung volumes as determined by&#xD;
      computed tomography (CT) scanning at 6 weeks in two study arms based on subjects' blinded&#xD;
      bronchoscopic intervention.&#xD;
&#xD;
      Initial assessment will comprise&#xD;
&#xD;
        -  Clinical evaluation&#xD;
&#xD;
        -  Full pulmonary function tests (PFTs) - static and dynamic lung volumes and gas transfer&#xD;
&#xD;
        -  SGRQ&#xD;
&#xD;
        -  Dyspnoea Score&#xD;
&#xD;
        -  CT scan&#xD;
&#xD;
      Suitable patients will then be randomised to receive either autologous blood, or normal&#xD;
      saline injected into the target airways.&#xD;
&#xD;
      Procedures in all patients will be carried out under conscious sedation and/or anaesthesia.&#xD;
      After bronchoscopic examination of the airways, 100ml of the patients own blood will be&#xD;
      collected using two 50ml syringes. A balloon catheter will be inserted into the target&#xD;
      segment and 25 mls of the blood will be injected via the balloon catheter. The balloon will&#xD;
      be inflated and maintained in position for about 6 minutes in order to minimise the risk of&#xD;
      overspill of blood into other areas of the lung. The balloon catheter will then be&#xD;
      repositioned in the next segment of the target lobe of the lung and the process repeated&#xD;
      until all the segments are treated. It is anticipated that the whole procedure will last&#xD;
      45-60 minutes, up to and including balloon removal.&#xD;
&#xD;
      The placebo arm will involve an identical protocol, except that injections of 30mls of 0.9%&#xD;
      saline will replace the injections of blood. 3 segments will be 'treated'. The blood&#xD;
      retrieved at the start of the procedure will be discarded.&#xD;
&#xD;
      A course of antibiotics or pulse of corticosteroids after the procedure will be at the&#xD;
      discretion of the investigator. Post-operative CXRs will only be ordered if there are&#xD;
      clinical indications (e.g. cough, fever, increased breathlessness).&#xD;
&#xD;
      Reassessment will occur at 6 weeks. This will be undertaken by a blinded assessment team with&#xD;
      no knowledge of which study arm a patient has been randomised into, and with no access to the&#xD;
      initial procedure record. This removes expectation and subjectivity from the assessment.&#xD;
      Assessment will consist of the following:&#xD;
&#xD;
        -  Clinical evaluation&#xD;
&#xD;
        -  Full pulmonary function tests (PFTs) - static and dynamic lung volumes and gas transfer&#xD;
&#xD;
        -  SGRQ&#xD;
&#xD;
        -  Dyspnoea Score&#xD;
&#xD;
        -  Blinding questionnaire for patient and assessment team&#xD;
&#xD;
        -  CT scan&#xD;
&#xD;
      After the assessments have been completed the patients will be un-blinded and informed which&#xD;
      treatment group they had been assigned to.&#xD;
&#xD;
      Subjects will be made aware that the process is expected to be irreversible. However, if&#xD;
      there are any problems during the bronchoscopy (for example worsening hypoxia), then the&#xD;
      procedure will be abandoned as soon as it is safe to do so.&#xD;
&#xD;
      A log of adverse and serious adverse events for each patient will be kept as part of the&#xD;
      safety monitoring of the trial.&#xD;
&#xD;
      Those who are entered into the control arm of the study will be offered the real procedure at&#xD;
      the end of the study if benefits are apparent&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of scarring and volume loss on CT scanning</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To ensure no significant lung function deteriorations at 6 weeks post-procedure</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Emphysema</condition>
  <arm_group>
    <arm_group_label>Autologous blood</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will have 50mls of autologous blood injected into each of 3 bronchopulmonary segments during bronchoscopy under conscious sedation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will have 50mls of normal saline injected into each of 3 bronchopulmonary segments during bronchoscopy under conscious sedation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous blood</intervention_name>
    <description>50mls of autologous blood injected into each of 3 bronchopulmonary segments.</description>
    <arm_group_label>Autologous blood</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>50mls of normal saline injected into each of 3 bronchopulmonary segments.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-80 years&#xD;
&#xD;
          -  Moderate to severe airflow obstruction FEV1 &lt;50% Predicted&#xD;
&#xD;
          -  Severe dyspnoea - mMRC ≥2&#xD;
&#xD;
          -  Hyperinflation - total lung capacity (TLC) ≥100% predicted, RV ≥150% predicted&#xD;
&#xD;
          -  Optimum COPD treatment for at least 6 weeks&#xD;
&#xD;
          -  No COPD exacerbation for at least 6 weeks&#xD;
&#xD;
          -  Less than 3 admissions for exacerbation in the preceding 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient unable to provide informed consent&#xD;
&#xD;
          -  Total lung CO uptake (TLCO) &lt;15% predicted and FEV1 &lt;15% predicted&#xD;
&#xD;
          -  pO2 on air &lt;6.0kPa&#xD;
&#xD;
          -  pCO2 on air &gt;8.0kPa&#xD;
&#xD;
          -  Other major medical illness, e.g. lung cancer that will limit participation&#xD;
&#xD;
          -  Clinically significant bronchiectasis&#xD;
&#xD;
          -  Large bulla - more than 1/3 of hemithorax volume (i.e. where bullectomy would be more&#xD;
             suitable) on CT scan&#xD;
&#xD;
          -  Arrhythmia or cardiovascular disease that poses a risk during procedure&#xD;
&#xD;
          -  Prednisolone dose greater than 10mg a day&#xD;
&#xD;
          -  Prior LVRS or lobectomy&#xD;
&#xD;
          -  Lung nodule requiring surgery&#xD;
&#xD;
          -  Female of childbearing age with positive pregnancy test&#xD;
&#xD;
          -  Subject participated in a research study of investigational drug or device in prior 30&#xD;
             days&#xD;
&#xD;
          -  Subject taking clopidogrel, warfarin, or other anticoagulants and unable to abstain&#xD;
             for 5 days pre-procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pallav Shah, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chelsea and Westminster Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chelsea and Westminster NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Kobayashi H, Kanoh S. [Bronchoscopic autologous blood injection for lung volume reduction]. Nihon Kokyuki Gakkai Zasshi. 2009 Sep;47(9):765-71. Japanese.</citation>
    <PMID>19827579</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>February 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <last_update_submitted>December 19, 2013</last_update_submitted>
  <last_update_submitted_qc>December 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Emphysema, lung volume reduction, autologous blood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

